Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer model.

Pritchard JE, Dillon PM, Conaway MR, Silva CM, Parsons SJ.

Oncology. 2012;83(6):305-20. doi: 10.1159/000341394. Epub 2012 Sep 5.

2.

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.

J Natl Cancer Inst. 2004 Jun 16;96(12):926-35.

PMID:
15199112
3.

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.

Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ.

Breast Cancer Res. 2011 Mar 1;13(2):R21. doi: 10.1186/bcr2833.

4.

Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.

Chang SB, Miron P, Miron A, Iglehart JD.

J Surg Res. 2007 Mar;138(1):37-44. Epub 2006 Nov 15.

PMID:
17109887
5.
6.

MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.

Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB.

Oncogene. 2002 Jun 6;21(25):4000-8.

7.

WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.

Sikora MJ, Jacobsen BM, Levine K, Chen J, Davidson NE, Lee AV, Alexander CM, Oesterreich S.

Breast Cancer Res. 2016 Sep 20;18(1):92. doi: 10.1186/s13058-016-0748-7.

8.

Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells.

Pietras RJ, Márquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M.

Steroids. 2005 May-Jun;70(5-7):372-81. Epub 2005 Mar 25.

PMID:
15862820
9.

Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.

Ikeda H, Taira N, Nogami T, Shien K, Okada M, Shien T, Doihara H, Miyoshi S.

Cancer Sci. 2011 Nov;102(11):2038-42. doi: 10.1111/j.1349-7006.2011.02050.x. Epub 2011 Sep 1.

10.

Inositol hexaphosphate (IP6) enhances the anti-proliferative effects of adriamycin and tamoxifen in breast cancer.

Tantivejkul K, Vucenik I, Eiseman J, Shamsuddin AM.

Breast Cancer Res Treat. 2003 Jun;79(3):301-12.

PMID:
12846414
11.

AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.

Ribas R, Pancholi S, Guest SK, Marangoni E, Gao Q, Thuleau A, Simigdala N, Polanska UM, Campbell H, Rani A, Liccardi G, Johnston S, Davies BR, Dowsett M, Martin LA.

Mol Cancer Ther. 2015 Sep;14(9):2035-48. doi: 10.1158/1535-7163.MCT-15-0143. Epub 2015 Jun 26.

12.
13.

Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.

Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA.

Int J Cancer. 2010 Jan 15;126(2):545-62. doi: 10.1002/ijc.24750.

14.

ADAM12 induces estrogen-independence in breast cancer cells.

Roy R, Moses MA.

Breast Cancer Res Treat. 2012 Feb;131(3):731-41. doi: 10.1007/s10549-011-1431-4. Epub 2011 Mar 9.

15.

Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.

Chang HL, Sugimoto Y, Liu S, Ye W, Wang LS, Huang YW, Lin YC.

Anticancer Res. 2006 May-Jun;26(3A):1773-84.

17.

[Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells].

Zhen LL, Zhu X, Zheng W, Wang XY, Wu ZY.

Ai Zheng. 2006 Jul;25(7):839-43. Chinese.

PMID:
16831274
18.

A naringenin-tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells.

Hatkevich T, Ramos J, Santos-Sanchez I, Patel YM.

Exp Cell Res. 2014 Oct 1;327(2):331-9. doi: 10.1016/j.yexcr.2014.05.017. Epub 2014 May 29.

PMID:
24881818
19.

Functional interaction of fibroblast growth factor-8, bone morphogenetic protein and estrogen receptor in breast cancer cell proliferation.

Masuda H, Otsuka F, Matsumoto Y, Takano M, Miyoshi T, Inagaki K, Shien T, Taira N, Makino H, Doihara H.

Mol Cell Endocrinol. 2011 Aug 22;343(1-2):7-17. doi: 10.1016/j.mce.2011.05.037. Epub 2011 Jun 1.

PMID:
21664418
20.

Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.

Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Steelman LS, McCubrey JA.

Oncotarget. 2011 Aug;2(8):610-26.

Supplemental Content

Support Center